Literature DB >> 21871025

Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan.

Feng-Woei Tsay1, Hui-Hwa Tseng, Ping-I Hsu, Kai-Ming Wang, Ching-Chang Lee, Shiuh-Nan Chang, Huay-Min Wang, Hsien-Chung Yu, Wen-Chi Chen, Nan-Jing Peng, Kwok-Hung Lai, Deng-Chyang Wu.   

Abstract

BACKGROUND AND AIMS: Most clinical trials concerning sequential therapy have been conducted in Italy. The efficacy of sequential therapy for Helicobacter pylori (H. pylori) eradication in Asia remains unclear. The aim of this study was to compare the efficacy of sequential therapy with standard triple therapy in Taiwan.
METHODS: From January 2005 to December 2009, 233 H. pylori-infected patients receiving either a 10-day sequential therapy (40 mg pantoprazole and 1 g amoxicillin, twice daily, for the initial 5 days, followed by 40 mg pantoprazole, 500 mg clarithromycin, and 500 mg metronidazole, twice daily, for the subsequent 5 days, n = 118) or a 7-day standard triple therapy (40 mg pantoprazole, 500 mg clarithromycin, and 1 g amoxicillin twice daily for 7 days, n = 115) were included in the retrospective study. All the patients underwent a follow-up endoscopy with a rapid urease test and histological examination or a urea breath test at 8 weeks after the end of anti-H. pylori therapy to assess H. pylori status. RESULT: Intention-to-treat analysis demonstrated a significantly higher eradication rate for the sequential group than for the triple group (93% vs 80%, respectively, P = 0.003). Per-protocol analysis also showed similar results (93% vs 80%, P = 0.005). Both groups had similar frequencies of adverse events (29% vs 22%) and drug compliance (98% vs 97%).
CONCLUSION: Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. The novel treatment can be used as a first-line therapy for H. pylori infection for Taiwanese.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21871025     DOI: 10.1111/j.1440-1746.2011.06885.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Current Consensus and Remaining Questions Regarding the Diagnosis and Treatment of Helicobacter pylori Infection.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09

2.  Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.

Authors:  Jae Jin Hwang; Dong Ho Lee; Ae-Ra Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Authors:  Can Dolapcioglu; Aysun Koc-Yesiltoprak; Emel Ahishali; Aziz Kural; Hatice Dolapcioglu; Aliye Soylu; Resat Dabak
Journal:  Int J Clin Exp Med       Date:  2014-08-15

Review 4.  Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.

Authors:  Shan Zhao; Yan Lv; Jian-Bin Zhang; Bing Wang; Guo-Jun Lv; Xiao-Jun Ma
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

5.  Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.

Authors:  Wei-Chen Tai; Chih-Ming Liang; Chen-Hsiang Lee; Chien-Hua Chiu; Ming-Luen Hu; Lung-Sheng Lu; Yuan-Hung Kuo; Chung-Mou Kuo; Yi-Hao Yen; Chung-Huang Kuo; Shue-Shian Chiou; Keng-Liang Wu; Yi-Chun Chiu; Tsung-Hui Hu; Seng-Kee Chuah
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

6.  The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.

Authors:  Kwang Hyun Chung; Dong Ho Lee; Eunhyo Jin; Yuri Cho; Ji Yeon Seo; Nayoung Kim; Sook Hyang Jeong; Jin Wook Kim; Jin-Hyeok Hwang; Cheol Min Shin
Journal:  Gut Liver       Date:  2014-11-15       Impact factor: 4.519

7.  7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan.

Authors:  Sung-Shuo Kao; Wen-Chi Chen; Ping-I Hsu; Kwok-Hung Lai; Hsien-Chung Yu; Hui-Hwa Cheng; Nan-Jing Peng; Chiun-Ku Lin; Hoi-Hung Chan; Wei-Lun Tsai; Huay-Min Wang; Tzung-Jiun Tsai; Kung-Hung Lin; Feng-Woei Tsay
Journal:  Gastroenterol Res Pract       Date:  2012-07-22       Impact factor: 2.260

8.  Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.

Authors:  Chung-Chuan Chan; Nai-Hsuan Chien; Chia-Long Lee; Yi-Chen Yang; Chih-Sheng Hung; Tien-Chien Tu; Chi-Hwa Wu
Journal:  BMC Gastroenterol       Date:  2015-12-03       Impact factor: 3.067

9.  First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan.

Authors:  Chih-Ming Liang; Chien-Hua Chiu; Hsing-Ming Wang; Wei-Chen Tai; Chih-Chien Yao; Cheng-En Tsai; Chung-Mou Kuo; Yi-Chun Chiu; Keng-Liang Wu; Chen-Hsiang Lee; Kai-Lung Tsai; Chih-Fang Huang; Seng-Kee Chuah
Journal:  Biomed Res Int       Date:  2017-12-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.